Newtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond.

Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight.

Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time ?

whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.